Barinthus Bio’s VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B OXFORD, United Kingdom, June 06, 2024 [….]
Barinthus Bio’s VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B
![](https://biobuzz.io/wp-content/uploads/2024/06/Annabel-Article-Photos-5-300x300.png)